Clinical, microbiological, and laboratory predictors of on- and off-label dalbavancin treatment failure
The observed TF rate was high, particularly in off-label uses and among individuals with multiple comorbidities or IV drug use. More evidence is needed to better define the optimal patient profile for effective dalbavancin treatment.
Authors
- Vincenzo Scaglione (ORCID: https://orcid.org/0000-0002-2911-2255)
- Emilia Mazzitelli (ORCID: https://orcid.org/0000-0002-8884-2346)
- Anna Maria Cattelan (ORCID: https://orcid.org/0000-0003-2869-2945)
- Luigi Salmaso (ORCID: https://orcid.org/0000-0001-6501-1585)
- Elena Barzizza (ORCID: https://orcid.org/0000-0002-6389-887X)
- Francesca Venturini (ORCID: https://orcid.org/0000-0003-0396-4377)
- Daniele Mengato (ORCID: https://orcid.org/0000-0003-1374-1505)
- Elisabetta Mariavittoria Giunco
Institutions
- University of Padua (IT)
Publication Details
- Journal
- Journal of Global Antimicrobial Resistance
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1016/j.jgar.2025.05.014
- Citations
- 1
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 1.39